TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04521621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gebasaxturev
Description: Participants receive gebasaxturev intratumorally for 1 28-day cycle followed by 7 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants receive pembrolizumab intravenously for 1 28-day cycle followed by 34 21-day cycles.
Study: NCT03369067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology + Dexcom G6
Description: Subjects will use the Tandem t:slim X2 with Control-IQ Technology and Dexcom G6 CGM to control their glycemia. The Tandem t:slim X2 with Control-IQ device is an automated insulin delivery pump that automatically adjusts insulin delivery to predicted and prevailing glucose levels, as measured by a Dexcom G6 continuous glucose monitor \[CGM\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom CGM G5
Description: The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dexcom CGM G5
Description: The Dexcom G5 CGM is a subcutaneous glucose sensor that provides an estimate of the prevailing blood glucose concentration approximately every 5 minutes.The Dexcom G5 sensor alerts the user if the prevailing glucose concentration is higher or lower than predetermined thresholds, or if it is changing too fast. In addition, the Share/Follow functionality of the Dexcom G5 allows up to 5 people (followers) to receive in real-time information about the current blood glucose concentration and rate of change.~The Dexcom G5 system will be used by participants and clinical study staff to monitor glucose levels 24h/day during the camp, ensure participants safety, and compute glycemic control outcomes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Subcutaneous Insulin Infusion
Description: Subjects will use a subcutaneous pump to deliver insulin and control their glycemia.
Study: NCT01928342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule without coenzyme A.
Study: NCT01938105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nimotuzumab+chemoradiotherapy
Description: Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.~--------------------------------------------------------------------------------
Study: NCT03729011

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Volatile agent
Description: Patients will receive volatile agent to provide general anaesthesia, including CPB period. Volatile agents will be administered from anesthesia induction to the end of surgery. Concentration (MAC) of volatile agent will be selected by anaesthesiologist according to clinical situation and patient features.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients will receive propofol and no volatile agent. Propofol will be used for induction and maintenance of anesthesia.
Study: NCT02608762

Intervention type: RADIATION
Intervention: standard adjuvant local radiation therapy or cranial radiation therapy
Study: NCT02308332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eviplera
Description: switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
Study: NCT04178512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control
Description: prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control
Description: prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug:dexamethasone in group Dexamethasone,fentanyl in group Fentanyl,normal saline 0.9%in group Control
Description: prevention of shivering after spinal anesthesia in patients undergoing trans urethral prostatectomy through injection of spinal additives
Study: NCT02443922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride 2mg qam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100mg qam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin as prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin as prescribed
Study: NCT01050010

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: dedicated extremity MRI
Study: NCT02349568

Intervention type: PROCEDURE
Intervention: High risk group
Description: Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.

Intervention type: PROCEDURE
Intervention: Intermediate risk group
Description: Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
Study: NCT00871351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
Study: NCT01289041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Study: NCT01213043

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolastin-C, 60 mg/kg
Description: 60 mg/kg weekly infusion of Prolastin-C for 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolastin-C, 120 mg/kg
Description: 120 mg/kg weekly infusion of Prolastin-C for 8 weeks
Study: NCT04162990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle remodeling Intervention
Description: Participants will be received 2 phases of intervention of lifestyle remodeling, 3 months for each phase, which contained cognitive stimulating activities and physical activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Does Comparator: regular treatment
Description: Participants in this group would be treated as usual, which contained the healthy education.
Study: NCT00782977

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Nasal oxygen therapy
Description: Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen therapy
Description: Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen therapy
Description: Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
Study: NCT02959671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower Anterior EXD-952 Self-ligating Brackets
Description: Placement of EXD-952 Self-ligating Brackets on mandibular incisors
Study: NCT03169192

Intervention type: DRUG
Intervention: Zoledronic Acid
Description: intravenous injections once every 3 months
Study: NCT01175772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytophosphan, Celecoxib, Methotrexate
Description: Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer~* Cytophosphan tab 50 mg -1x1 per day, continuous~* Celecoxib tab 200 mg - 1x2 per day, continuous~* Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly
Study: NCT02655471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir and Zidovudine
Description: Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
Study: NCT02887989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Health and Wellness Channel
Description: Relaxing content broadcast passively on the patient in-room television channel.
Study: NCT01886638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir
Study: NCT01567943

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Behavioral reinforcement for alcohol abstinence
Study: NCT02831179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03355963

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline injection
Description: The control group: received an IC 1 ml saline injection one day after the penile Doppler/trimix test.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A 50 units
Description: The treatment group B: received a single IC injection of BTX-A 50 units one day after the penile Doppler/trimix test.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A 100 units
Description: The treatment group C: received a single IC injection of BTX-A 100 units one day after the penile Doppler/trimix test.
Study: NCT02617264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPOT
Description: Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
Study: NCT02468609

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultralow-Dose-CT
Description: Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
Study: NCT01033292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSI-201
Description: IV infusion, 5.6 mg/kg
Study: NCT04290065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The patient will be lying supine, relaxed. The physiotherapist, located at the patient's head, will cover the occipital bone with one hand while the palm of the hand will rest on the lambdoid suture, and the fingers will be introduced into the suboccipital space. The other hand, with a glove, will be inserted into the patient's oral cavity, resting respectively the index and middle fingers, each in an upper dental hemiarchy, on the chewing face of the tooth. An axial traction will be carried out until the three tension barriers of equal size between them are overcome, in an estimated time between 1.50 and 3 minutes. All manual therapy sessions will be performed by the same physiotherapist, following the same protocol and under the same conditions.
Study: NCT01464008

Intervention type: DRUG
Intervention: Pegylated interferon alfa-2a and ribavirin
Description: all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
Study: NCT01129531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AGN-214868
Description: Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
Study: NCT03550430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: alpha/delta neurofeedback
Description: neurofeedback training protocol seeking to decrease the alpha/delta ratio, by simultaneous rewarding alpha and inhibiting delta activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: beta/theta neurofeedback
Description: neurofeedback training protocol seeking to decrease the beta/theta ratio, by simultaneous rewarding beta and inhibiting theta activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diary completion
Description: completion of diary relating to participants' experience of tinnitus intensity, interference, coping, harm and disability. Rated three times daily on numerical scale (0 - 10) for two weeks.
Study: NCT02423590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatorsen (OGX-427)
Description: Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent.
Study: NCT02030912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 doses of amoxicillin daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 doses of minocycline daily for five days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 2 doses of placebo daily for five days
Study: NCT04944394

Intervention type: OTHER
Intervention: online questionnaire
Description: Administration of an online questionnaire (Limesurvey platform) at M0~- This questionnaire includes a characterization of the professional (center, profession, usual department and department during the health crisis, family situation). Generic stress factors, the traumatic impact of the crisis and collective and individual coping strategies are also collected.

Intervention type: OTHER
Intervention: questionnaire survey
Description: A questionnaire survey of the chief physician of the intensive care unit of each hospital will make it possible to characterize the support provided by the institution and how it changed over time
Study: NCT04560205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 4-8mg/kg with 400mg maximum dose of Tocilizumab will be given in 60 minutes I/V infusion, and dose will be repeated after 12-24 hours according to clinical as well as laboratory parameters.~Customized decision for Tocilizumab usage will be made by attending infectious diseases physician, comfort with Tocilizumab usage, bacterial co-infection and duration of Ventilation.
Study: NCT02483013

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: whitening dentifrices
Description: Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
Study: NCT01432015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosaprepitant
Description: Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Placebo
Description: One pill administered on days 1-3 in conjunction with Fosaprepitant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo
Description: 100 cc of IV placebo administered on day in conjunction with Aprepitant
Study: NCT03661996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-4975-05
Description: Osteoarthritis (OA) intra-articular injection of CNTX-4975-05

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine without epinephrine
Description: 15 mL lidocaine intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine without epinephrine
Description: 15 mL lidocaine intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine without epinephrine
Description: 15 mL lidocaine intra-articular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine without epinephrine
Description: 15 mL lidocaine intra-articular injection
Study: NCT01005940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device
Description: Mandibular advancement device made to subject specific specifications